The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 356:2648-2649 June 21, 2007 Number 25
NextNext

Varicella Vaccine

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited
-E-mail When Letters Appear

More Information
-Related Article
by Chaves, S. S.
-PubMed Citation
To the Editor: Chaves et al. (March 15 issue)1 use complex statistical models, based on nonvalidated estimates and uncertain diagnoses, to conclude from epidemiologic data that vaccine-induced immunity to varicella–zoster virus (VZV) wanes. Our data based on serologic testing indicate that primary vaccine failure is the main reason for breakthrough varicella infection in 15 to 20% of vaccinees; in 20 of 84 children (24%) who were given one dose of vaccine, VZV antibodies failed to develop.2

Chaves and colleagues used an estimate of primary vaccine failure and cannot distinguish failure to elicit immunity from waning immunity. When directly tested in . . . [Full Text of this Article]


This article has been cited by other articles:


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.